INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Foghorn Therapeutics Inc.

Foghorn Therapeutics shares fell $0.90, or 30.82%, to $2.02 on October 2, 2026, after Foghorn and Lilly decided not to advance the FHD-909 program or their selective SMARCA2 degrader collaboration. Foghorn said it would cut its workforce by approximately 40% and that its cash would fund priority programs into the second half of 2029. Pomerantz LLP is investigating whether the company and certain officers or directors engaged in securities fraud or other unlawful business practices; the investigation is not a finding of wrongdoing.

Analysis

The core repricing is a loss of partnered-program optionality and a narrower proprietary pipeline—not the law firm’s investigation notice. That notice is not evidence of misconduct, and absent new allegations or filings it is unlikely to be a durable standalone catalyst. The October 1 program decisions may also reduce near-term external validation and future collaboration economics; however, Lilly’s withdrawal does not establish anything about Lilly’s other programs or Foghorn’s remaining assets. Management’s stated runway into the second half of 2029 is a company claim, not a substitute for checking cash, quarterly burn, restructuring costs, and the assumptions behind that estimate. A 40% workforce reduction may extend runway, but can also delay execution and increase reliance on fewer clinical milestones. Over the next 1–3 months, focus on updated cash/burn disclosures and whether the company can articulate funded, measurable milestones for its priority portfolio. Over 6–18 months, remaining-program data are the main potential source of value recovery—or further downside if the pipeline proves thin. The contrarian point is that the litigation headline may look incremental after the earlier repricing, while investors may still underweight the operational risk of concentrating resources in fewer programs. Conversely, treating the announced runway as assured could overstate downside protection.

Key Decisions for Investors

• No trade on the investigation notice alone: it is a solicitation to investigate, not a finding, and appears subsequent to the material program news. Reassess only if a complaint, regulatory filing, or credible disclosure evidence adds new facts.
• Keep FHTX on a catalyst-driven watchlist rather than initiating a fresh short solely on the prior selloff; small-cap biotech rebounds and clinical headlines can create sharp squeeze risk. Verify current price, liquidity, borrow availability, and option-implied volatility before considering defined-risk downside exposure.
• Before considering a long, review the next filing for cash balance, quarterly operating burn, restructuring charges, and the basis for the stated runway; require specific timelines and funding for priority-program milestones. A shorter-than-stated runway or further program attrition would falsify the stabilization thesis.
• Monitor clinical updates over the next 6–18 months: credible progress in retained programs could restore pipeline value, while missed milestones, delays, or additional cuts would reinforce the case that the collaboration exits left insufficient diversification.